AMT's Lead Product Poised to Address Major Liver Disease; European Patent Office Grants Patent for Treatment of Non-alcoholic Steatotic Hepatitis.

0 Comments | M2 Presswire, January, 2008

M2 PRESSWIRE-28 January 2008-AMT: AMT's Lead Product Poised to Address Major Liver Disease; European Patent Office Grants Patent for Treatment of Non-alcoholic Steatotic Hepatitis(C)1994-2008 M2 COMMUNICATIONS LTD

RDATE:28012008

Amsterdam, The Netherlands -- AMT (Euronext: AMT), a leader in the field of human gene therapy, today announced that the European Patent Office (EPO) has granted the company an important patent for the treatment of Non-Alcoholic Steatotic Hepatitis (NASH) with its lead product AMT-11. AMT has a similar patent pending with the U.S. Patent and Trademark Office.

The most common liver disorder in the Western world, non-alcoholic fatty liver disease (NAFLD), affects 20 to 40 percent of the general population. At least...